发明名称 |
Ganglioside Transmucosal Formulations |
摘要 |
A transmucosal formulation comprising a ganglioside and a mucosal absorption enhancer, as well as a method of treating or preventing Parkinson's disease in a human patient in need thereof comprising parenterally administering such a transmucosal formulation to said patient. |
申请公布号 |
US2015283158(A1) |
申请公布日期 |
2015.10.08 |
申请号 |
US201414520206 |
申请日期 |
2014.10.21 |
申请人 |
LZ Therapeutics, Inc. |
发明人 |
Koleng John J.;Florentine Robert;Anderson David W.;Anderson David W. |
分类号 |
A61K31/7028;A61M13/00;A61M31/00;A61M15/00;A61K45/06;A61K9/00 |
主分类号 |
A61K31/7028 |
代理机构 |
|
代理人 |
|
主权项 |
1. A pharmaceutical composition for treatment or prevention of a central nervous system (CNS) disease or condition in a human patient amenable to treatment by therapeutic administration of an GM1, comprising a formulation for transmucosal administration comprising: GM1 and at least one permeation-enhancing agent effective to enhance transmucosal drug uptake; at least one buffer; at least one solvent; and at least one osmolarity agent. |
地址 |
Malvern PA US |